Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Bosutinib Monohydrate

FDA-approved product (tablet, oral), marketed as Bosulif, Bosutinib Monohydrate.

Registered studies
2
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Bosutinib Monohydrate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Chronic myelogenous leukemia
  • Myeloid leukemia

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Bcr-abl tyrosine kinase inhibitors
FDA pharmacologic class
Kinase Inhibitor FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA43.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli54.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae30.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis43.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

2registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Bosutinib Monohydrate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.6 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.0 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.0 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.9 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Bosutinib Monohydrate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Glasdegib-Based Treatment Combinations for the Treatment of Patients With Relapsed Acute Myeloid Leukemia Who Have Undergone Hematopoietic Cell Transplantation

    NCT04655391 · start 2022-06-25

    Registered record
    Registry ID
    NCT04655391
    Conditions
    Recurrent Acute Myeloid Leukemia
    Interventions
    Bosutinib Monohydrate; Decitabine; Enasidenib Mesylate; Gilteritinib Fumarate; Glasdegib Maleate; Ivosidenib; Venetoclax
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Withdrawn
    Start
    2022-06-25
    Completion
    2023-12-15
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRecurrent Acute Myeloid Leukemia
    InterventionBosutinib Monohydrate; Decitabine; Enasidenib Mesylate; Gilteritinib Fumarate +3 more
    PhasePhase 1
    Registry statusWithdrawn

  • Testing the Addition of Ruxolitinib to the Usual Treatment (Tyrosine Kinase Inhibitors) for Chronic Myeloid Leukemia

    NCT03654768 · start 2018-10-24

    Registered record
    Registry ID
    NCT03654768
    Conditions
    Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
    Interventions
    Bosutinib; Dasatinib; Laboratory Biomarker Analysis; Nilotinib; Ruxolitinib; Imatinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2018-10-24
    Completion
    2028-07-01
    Enrolment
    81

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
    InterventionBosutinib; Dasatinib; Laboratory Biomarker Analysis; Nilotinib +2 more
    PhasePhase 2
    Registry statusActive not recruiting